Format

Send to

Choose Destination
J Tissue Eng Regen Med. 2017 Sep;11(9):2425-2442. doi: 10.1002/term.2131. Epub 2016 Apr 25.

Translational issues for human corneal endothelial tissue engineering.

Soh YQ1,2, Peh GSL1,3, Mehta JS1,2,3,4.

Author information

1
Tissue Engineering and Stem Cell Group, Singapore Eye Research Institute, Singapore.
2
Singapore National Eye Centre, Singapore.
3
Ophthalmology Academic Clinical Programme, Duke-NUS Graduate Medical School, Singapore.
4
Department of Clinical Sciences, Duke-NUS Graduate Medical School, Singapore.

Abstract

Corneal endothelial disorders collectively represent a significant healthcare burden in most developed nations, and corneal transplantation is currently the only treatment available for patients with poor visual acuity and corneal blindness secondary to endothelial failure. Although vision in these patients can be restored by transplantation, the global demand for donor human corneas is far in excess of what can be provided for by eye banks around the world, and this deficit is set to increase with an ageing global population. As such, there has been a pressing need to explore novel and more sustainable options for the treatment of corneal endothelial diseases. In recent years, significant progress has been made not only in the development of corneal endothelial cell culture techniques, but also in the exploration of various translational strategies. Considered together, we are now much closer to attaining success in the treatment of corneal endothelial diseases via a cell-based, tissue-engineering approach. The aim of this review article is to provide an update of the translational issues currently facing human corneal endothelial cell therapy.

KEYWORDS:

cell markers; cornea; endothelial-mesenchymal transition; endothelium; human corneal endothelial cells; keratoplasty

PMID:
27109004
DOI:
10.1002/term.2131
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center